Lori Wirth, MD
Medical Oncology · Boston, MANPI 1750344008
Payments from drug & device makers
Across 488 payments — averaging $14,584 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$5M
- Novartis$827K
- Eisai Inc.$371K
- Merck$222K
- Lilly USA, LLC$216K
- Regeneron$129K
- plus $336K from 17 others
Across 8 payments — averaging $3699.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$24K
- Novartis Pharma AG$3K
- F. Hoffmann-la Roche AG$2K
- Regeneron$957
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 84 | $5,016,506 |
| Novartis | 10 | $826,585 |
| Eisai Inc. | 225 | $370,965 |
| Merck | 28 | $222,323 |
| Lilly USA, LLC | 6 | $215,531 |
| Regeneron | 25 | $128,786 |
| Bayer | 33 | $82,078 |
| AstraZeneca | 8 | $54,764 |
| Ascendis Pharma Endocrinology Inc | 2 | $43,350 |
| Exelixis Inc. | 9 | $42,914 |
| Eisai CO., LTD. | 21 | $28,632 |
| Coherus Oncology, Inc. | 7 | $17,486 |
| LEO Pharma AS | 7 | $16,713 |
| Novartis Pharma AG | 4 | $16,275 |
| Hoffmann-la Roche Limited | 2 | $10,821 |
| EMD Serono, Inc. | 1 | $4,793 |
| Sanofi US Services Inc. | 1 | $4,150 |
| Merck Healthcare Kgaa | 1 | $3,500 |
| AbbVie | 5 | $3,164 |
| Blueprint Medicines Corporation | 2 | $2,856 |
| Illumina, Inc. | 1 | $2,544 |
| Genentech USA, Inc. | 1 | $2,075 |
| Taiho Oncology, Inc. | 5 | $183 |
How this compares
$7,116,992 in reported general payments places this provider in the 90th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Boston
- Otto MetzgerBoston$141.9M
- Suzanne GeorgeBoston$88.5M
- Pasi Antero JanneBoston$67.2M
- Erica MayerBoston$51.8M
- Toni ChoueiriBoston$28.3M
- Laura SpringBoston$22.9M
- James ClearyBoston$18.8M
- Marlise LuskinBoston$18.7M
- Ana Garrido-CastroBoston$18M
- Jacob LaubachBoston$17.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.